Ultimovacs – executive interview

Published on 7 March 2022

Ultimovacs is a biotechnology company developing novel immunotherapies against cancer. The lead product candidate, UV1, is a peptide-based vaccine against the universal cancer antigen telomerase (hTERT). Around 85% of all cancer types express high levels of hTERT. Therefore, UV1 has broad potential in a variety of different settings and combinations with other cancer treatments.

In this video, chief executive officer Carlos de Sousa reviews the company’s broad R&D pipeline and explains multiple upcoming catalysts.

Share this with friends and colleagues